3 Numbers That Don’t Lie About British American Tobacco plc

Is British American Tobacco plc (LON:BATS) a buy? Roland Head takes a closer look at three key numbers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

british american tobacco / imperial tobaccoThe current investment case for British American Tobacco (LSE: BATS) (NYSE: BTI.US) is a little confusing. On the one hand, it has all the hallmarks of a great income stock.

On the other hand, I believe the tobacco industry is in decline, and BAT’s total sales have been falling for a number of years.

BAT’s shares aren’t cheap, either, and the firm has plenty of debt. So is BAT a buy, or a sell?

1. +23%

BAT shares have risen by 23% since 5 February, completing a remarkable rebound that has left the firm’s performance in-line with that of the FTSE 100 over the last year, up by around 2%.

However, February’s slide provided investors with a genuinely good opportunity to top up on BAT — at the shares’ lows, they offered a prospective yield of 5% and a 2014 forecast P/E of just 13.5, compared to today’s less compelling values of 4.1% and 16.6.

2. £250m

Last week, BAT confirmed it is involved in the complex takeover discussions between US firms Reynolds American, in which BAT has a 42% shareholding, and Lorillard.

In an article earlier this year, I suggested that BAT’s share of Reynolds’ profits could rise by around £250m per year, if the deal proceeds as it’s expected to, with Lorillard’s main brand, Newport, being absorbed into the Reynolds portfolio.

However, these extra profits won’t come cheap — BAT is expected to fund part of the Reynolds-Lorillard deal by purchasing new shares in Reynolds, which may require BAT to add to its £11.7bn debt pile.

3. -6.6%

In 2009, BAT reported group sales of 724bn cigarettes, or ‘stick equivalents’.

By the end of 2013, that total had fallen by 6.6% to 676bn. It’s a trend that’s expected to continue — BAT’s group sales fell by 1% during the first quarter of this year, despite volumes at its core brands rising by 6.3%.

The twist is that BAT’s increasing profitability and large share buybacks have meant that earnings per share — and the firm’s dividend — have continued to rise, regardless of falling sales, rewarding shareholders’ loyalty.

Can this balancing act continue? Rising debt costs could put pressure on the situation, as could a more rapid decline in sales.

However, I suspect BAT will continue to reward investors with an above-average dividend yield for some time to come, thanks to its global scale and profitability.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »